Fundz Deep Dive
Everything you need to win Flare Therapeutics — in one platform.
Who to reach, what to say, and why now on Flare Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Flare Therapeutics — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Flare Therapeutics and Merck Forge Clinical Trial Collaboration to Evaluate FX-909 with KEYTRUDA in Cancer Trial.
Oct 21, 2025•8 months ago
Contract Type
agreement
Description
Flare Therapeutics has announced a clinical trial collaboration and supply agreement with Merck to evaluate FX-909 in combination with KEYTRUDA® in a new cohort of their ongoing Phase 1 trial for metastatic urothelial cancer. This collaboration aims to enhance treatment options by investigating the combined effects of these therapies on cancer.
Related People
Suggested for you
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months